Patents Examined by Jeffrey S. Lundgren
  • Patent number: 10414758
    Abstract: Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR1; each R1 is independently H or C1-C6 alkyl; ring A is aryl; each R2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; R3 and R4 independently are H or C1-C6 alkyl; and R5 is halo, cyano, or C1-C6 alkyl.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 17, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
  • Patent number: 10413517
    Abstract: Methods and compositions which include or include the administration of a hydrophobic drug, prodrug thereof, salt thereof, isoform thereof, or a combination thereof; cyclodextrin, prodrug thereof, salt thereof, or a combination thereof; polyethylene glycol, propylene glycol, or combination thereof; and optionally, a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 17, 2019
    Assignee: UNIVERSITY OF NOTRE DAME DU LAC
    Inventors: Kasturi Haldar, Md. Suhail Alam
  • Patent number: 10413608
    Abstract: A method of using a compound in a phototherapy procedure includes administering to a subject in need of treatment a therapeutically effective amount of a thio-substituted nucleobase, nucleoside, nucleotide, and/or analogs thereof; and exposing the administered compound to electromagnetic radiation.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: September 17, 2019
    Assignee: Case Western Reserve University
    Inventors: Carlos E. Crespo-Hernandez, Marvin Pollum
  • Patent number: 10407440
    Abstract: Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for the treatment and/or prophylaxis wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy, and the like, each containing a thiazole derivative represented by the formula (I) wherein R1 represents aryl and the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: September 10, 2019
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Noriaki Uesaka, Takashi Sawada, Tomoyuki Kanda
  • Patent number: 10405538
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: September 10, 2019
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Yi Zheng, Jose Cancelas
  • Patent number: 10406133
    Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 10, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
  • Patent number: 10407383
    Abstract: The present invention relates to cyclopent(adi)ene compounds of formula I wherein the variables are as defined in the claims and description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: September 10, 2019
    Assignee: BASF SE
    Inventors: Pascal Bindschaedler, Wolfgang Von Deyn, Arun Narine, Karsten Koerber, Franz-Josef Braun
  • Patent number: 10400287
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: September 3, 2019
    Assignee: Myriad Genetics, Inc.
    Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid
  • Patent number: 10398691
    Abstract: The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and/or different CYP2D6 metabolizer status.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: September 3, 2019
    Assignee: RUNDLE RESEARCH, LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Patent number: 10391092
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 27, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Toshiya Tsuji, Rama K. Narla, Kristen Mae Hege
  • Patent number: 10385054
    Abstract: This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: August 20, 2019
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Craig McGowan, Serge Maria Aloysius Pieters, Stefaan Julien Last, Werner Embrechts, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 10383856
    Abstract: Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: August 20, 2019
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Gregory Hebrank, Wildon Farwell, Thomas Petzinger, Jr., Steven Dworetzky
  • Patent number: 10385062
    Abstract: Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the present application.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: August 20, 2019
    Assignees: Tianjin Hemay Bio-Tech Co., Ltd., Tianjin Michele Sci-Tech Development Co., Ltd.
    Inventors: Hesheng Zhang, Guanghuai Zeng, Yifei Gao
  • Patent number: 10376584
    Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: August 13, 2019
    Assignee: Progenics Pharmaceuticals, Inc.
    Inventors: Suketu P. Sanghvi, Thomas A. Boyd
  • Patent number: 10376525
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: August 13, 2019
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Patent number: 10376507
    Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 2-21 after stopping posaconazole.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: August 13, 2019
    Assignee: BOW RIVER LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Patent number: 10370719
    Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine and isolating corresponding mRNA in order to diagnose and treat acute kidney injury (AKI). In particular, certain embodiments relate to the method of capturing EMV from urine applied to a filter device that is capable of capturing EMV. Nucleic acids such as mRNA can be isolated from the EMV using an oligo(dT)-coated plate designed to accommodate the filter device and then used for further molecular analysis. Quantification of the collected nucleic acids may then be used in the diagnosis and/or treatment of IBD.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: August 6, 2019
    Assignees: Hitachi Chemical Co., Ltd., Hitachi Chemical Co. America, Ltd., The Regents of the University of California
    Inventors: Satish P. RamachandraRao, Ravindra Lall Mehta, Masato Mitsuhashi, Taku Murakami
  • Patent number: 10363246
    Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: July 30, 2019
    Assignee: Ovid Therapeutics Inc.
    Inventor: Matthew During
  • Patent number: 10364228
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: July 30, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman
  • Patent number: 10357486
    Abstract: This invention relates to the treatment of varying degrees of cognitive impairment associated with, for example, aging, Alzheimer's disease, schizophrenia with low dose administration of a PDE4 inhibitor, specifically roflumilast.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: July 23, 2019
    Assignee: UNIVERSITEIT MAASTRICHT
    Inventors: Jos Prickaerts, Marlies van Duinen, Anke Sambeth, Arjan Blokland